JP2004521961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004521961A5 JP2004521961A5 JP2003526415A JP2003526415A JP2004521961A5 JP 2004521961 A5 JP2004521961 A5 JP 2004521961A5 JP 2003526415 A JP2003526415 A JP 2003526415A JP 2003526415 A JP2003526415 A JP 2003526415A JP 2004521961 A5 JP2004521961 A5 JP 2004521961A5
- Authority
- JP
- Japan
- Prior art keywords
- carbamoyl
- solvate
- alkyl
- formula
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 113
- -1 hydroxy, amino, mercapto Chemical class 0.000 claims description 88
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000001475 halogen functional group Chemical group 0.000 claims description 11
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 6
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 150000002829 nitrogen Chemical group 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims 98
- 239000012453 solvate Substances 0.000 claims 95
- 150000001875 compounds Chemical class 0.000 claims 51
- 239000000651 prodrug Substances 0.000 claims 46
- 229940002612 prodrug Drugs 0.000 claims 46
- 241001465754 Metazoa Species 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 9
- 239000011230 binding agent Substances 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 6
- 241000282414 Homo sapiens Species 0.000 claims 6
- 229940123934 Reductase inhibitor Drugs 0.000 claims 6
- 239000003613 bile acid Substances 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 6
- 241000282412 Homo Species 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 230000001906 cholesterol absorption Effects 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 2
- 206010021024 Hypolipidaemia Diseases 0.000 claims 2
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 claims 2
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 claims 2
- 102000004316 Oxidoreductases Human genes 0.000 claims 2
- 108090000854 Oxidoreductases Proteins 0.000 claims 2
- 102000023984 PPAR alpha Human genes 0.000 claims 2
- 108010028924 PPAR alpha Proteins 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
- 210000001367 artery Anatomy 0.000 claims 2
- 229960005370 atorvastatin Drugs 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229960000672 rosuvastatin Drugs 0.000 claims 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- MQEZYLMJQKBGHE-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine Chemical compound S1NCCNC2=CC=CC=C21 MQEZYLMJQKBGHE-UHFFFAOYSA-N 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 229920002911 Colestipol Polymers 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical group O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 229950005357 bervastatin Drugs 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001258 dyslipidemic effect Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- ZADJRRFMOOACHL-WQICJITCSA-N ethyl (e,3s,5r)-7-[4-(4-fluorophenyl)spiro[chromene-2,1'-cyclopentane]-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C12=CC=CC=C2OC2(CCCC2)C(/C=C/[C@H](O)C[C@H](O)CC(=O)OCC)=C1C1=CC=C(F)C=C1 ZADJRRFMOOACHL-WQICJITCSA-N 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical group N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims 1
- 208000026621 hypolipoproteinemia Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical group C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000006492 vascular dysfunction Effects 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0121768A GB0121768D0 (en) | 2001-09-08 | 2001-09-08 | Chemical compounds |
| GB0209463A GB0209463D0 (en) | 2002-04-25 | 2002-04-25 | Chemical compounds |
| PCT/GB2002/004033 WO2003022286A1 (en) | 2001-09-08 | 2002-09-05 | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004038919A Division JP2004210794A (ja) | 2001-09-08 | 2004-02-16 | 高脂質血症の治療のための回腸胆汁酸運搬（ｉｂａｔ）阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004521961A JP2004521961A (ja) | 2004-07-22 |
| JP3616635B2 JP3616635B2 (ja) | 2005-02-02 |
| JP2004521961A5 true JP2004521961A5 (https=) | 2005-04-21 |
Family
ID=26246524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526415A Expired - Lifetime JP3616635B2 (ja) | 2001-09-08 | 2002-09-05 | 高脂質血症の治療のための回腸胆汁酸運搬（ｉｂａｔ）阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体 |
| JP2004038919A Pending JP2004210794A (ja) | 2001-09-08 | 2004-02-16 | 高脂質血症の治療のための回腸胆汁酸運搬（ｉｂａｔ）阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004038919A Pending JP2004210794A (ja) | 2001-09-08 | 2004-02-16 | 高脂質血症の治療のための回腸胆汁酸運搬（ｉｂａｔ）阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7132416B2 (https=) |
| EP (1) | EP1427423B9 (https=) |
| JP (2) | JP3616635B2 (https=) |
| KR (1) | KR100935623B1 (https=) |
| CN (1) | CN1582151A (https=) |
| AR (1) | AR037089A1 (https=) |
| AT (1) | ATE349214T1 (https=) |
| AU (1) | AU2002329387B2 (https=) |
| BR (1) | BRPI0212346B1 (https=) |
| CA (1) | CA2459449C (https=) |
| CO (1) | CO5570671A2 (https=) |
| CY (1) | CY1106348T1 (https=) |
| DE (1) | DE60217136T2 (https=) |
| DK (1) | DK1427423T5 (https=) |
| ES (1) | ES2278045T3 (https=) |
| HU (1) | HU227623B1 (https=) |
| IL (2) | IL160691A0 (https=) |
| IS (1) | IS7170A (https=) |
| MX (1) | MXPA04002179A (https=) |
| MY (1) | MY131995A (https=) |
| NO (1) | NO327041B1 (https=) |
| NZ (1) | NZ531796A (https=) |
| PL (1) | PL216023B1 (https=) |
| PT (1) | PT1427423E (https=) |
| RU (1) | RU2305681C2 (https=) |
| TW (1) | TWI331143B (https=) |
| UY (1) | UY27436A1 (https=) |
| WO (1) | WO2003022286A1 (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| SE0104333D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) * | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| PL375074A1 (en) * | 2002-06-20 | 2005-11-14 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) * | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| AU2008202120B2 (en) * | 2003-04-05 | 2009-12-17 | Albireo Ab | Use of an IBAT inhibitor for the treatment of prophylaxis of constipation |
| GB0314131D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| AR057828A1 (es) * | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| US7528448B2 (en) * | 2006-07-17 | 2009-05-05 | E.I. Du Pont De Nemours And Company | Thin film transistor comprising novel conductor and dielectric compositions |
| US8062824B2 (en) | 2006-07-17 | 2011-11-22 | E. I. Du Pont De Nemours And Company | Thermally imageable dielectric layers, thermal transfer donors and receivers |
| AU2008221673B2 (en) * | 2007-03-08 | 2013-03-28 | Albireo Ab | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
| US7666567B2 (en) | 2007-10-23 | 2010-02-23 | E. I. Du Pont De Nemours And Company | Negative imaging method for providing a patterned metal layer having high conductivity |
| US7666568B2 (en) * | 2007-10-23 | 2010-02-23 | E. I. Du Pont De Nemours And Company | Composition and method for providing a patterned metal layer having high conductivity |
| CA2744817C (en) * | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| EP2575821B1 (en) * | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| PL3400944T3 (pl) | 2010-11-04 | 2020-11-16 | Albireo Ab | Inhibitory ibat w leczeniu chorób wątroby |
| JP6097695B2 (ja) | 2010-11-08 | 2017-03-15 | アルビレオ アクチエボラグ | Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ |
| MX2013005110A (es) * | 2010-11-08 | 2013-08-21 | Albireo Ab | Inhibidores del ibat para el tratamiento de padecimientos metabolicos y condiciones relacionadas. |
| US20120114588A1 (en) * | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| CN104023727B (zh) * | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂 |
| CA2852957C (en) | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| CN105228615A (zh) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂 |
| US20140275090A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| EP3413877B1 (en) | 2016-02-09 | 2021-04-07 | Albireo AB | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
| CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| TWI822738B (zh) * | 2018-03-09 | 2023-11-21 | 瑞典商依洛比克斯公司 | 用於製備1,5-苯并噻氮呯化合物之方法 |
| US10428109B1 (en) | 2018-03-09 | 2019-10-01 | Elobix Ab | Process for the preparation of 1,5-benzothiazepine compounds |
| ES2942443T3 (es) | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| BR112020024479A2 (pt) * | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| ES2955799T3 (es) | 2019-02-06 | 2023-12-07 | Albireo Ab | Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares |
| HUE060905T2 (hu) * | 2019-02-06 | 2023-04-28 | Albireo Ab | Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| PL3923943T3 (pl) | 2019-02-12 | 2024-12-09 | Mirum Pharmaceuticals, Inc. | Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych |
| JP7689076B2 (ja) * | 2019-09-09 | 2025-06-05 | Ｅａファーマ株式会社 | １，５－ベンゾチアゼピン化合物を製造するための方法 |
| TWI877262B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其作為膽酸調節劑之用途 |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
| CA3158181A1 (en) * | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| ES2973549T3 (es) | 2019-12-04 | 2024-06-20 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares |
| TWI877263B (zh) * | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| TWI867107B (zh) | 2019-12-04 | 2024-12-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| WO2022166680A1 (zh) * | 2021-06-25 | 2022-08-11 | 苏州科睿思制药有限公司 | 奥德昔巴特的晶型及其制备方法和用途 |
| WO2023174937A1 (en) | 2022-03-16 | 2023-09-21 | Sandoz Ag | Particles comprising non-crystalline odevixibat |
| JP2025516153A (ja) | 2022-04-22 | 2025-05-27 | アルビレオ・アクチボラグ | Ａｓｂｔ阻害剤の皮下投与 |
| KR20250022025A (ko) | 2022-06-09 | 2025-02-14 | 알비레오 에이비 | 간염 치료 |
| CN119487013A (zh) | 2022-07-05 | 2025-02-18 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US20240173333A1 (en) | 2022-11-03 | 2024-05-30 | Albireo Ab | Treating Alagille Syndrome (ALGS) |
| EP4630112A1 (en) | 2022-12-09 | 2025-10-15 | Albireo AB | Cocrystals of odevixibat |
| AU2023390975A1 (en) | 2022-12-09 | 2025-06-05 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2024184924A1 (en) * | 2023-03-06 | 2024-09-12 | Rk Pharma Inc | "an improved process for the preparation of odevixibat and its crystalline forms" |
| WO2025093760A1 (en) | 2023-11-03 | 2025-05-08 | Albireo Ab | Treating pfic2 with odevixibat |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
| JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
| GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| DK0781278T3 (da) | 1994-09-13 | 2001-04-17 | Monsanto Co | Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse |
| GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
| NZ331813A (en) | 1996-03-11 | 2001-03-30 | G | Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
| MXPA99008417A (es) | 1997-03-11 | 2005-02-03 | Searle & Co | Terapia de combinacion que emplaza benzotiepinas inhibidoras de transporte de acido biliar ileal e inhibidores de hmg co-a reductasa. |
| DE69815180T2 (de) | 1997-03-14 | 2004-04-29 | Aventis Pharma Deutschland Gmbh | Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide |
| AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
| US6369220B1 (en) | 1997-12-19 | 2002-04-09 | Jinglin (James T.) Li | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides |
| GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
| DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| PL348508A1 (en) | 1998-12-23 | 2002-05-20 | Searle Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| CN1342090A (zh) | 1998-12-23 | 2002-03-27 | G·D·瑟尔有限公司 | 适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合 |
| JP2002533414A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ |
| EP1140191B1 (en) | 1998-12-23 | 2002-10-23 | G.D. Searle LLC. | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| DE69911058T2 (de) | 1998-12-23 | 2004-06-03 | G.D. Searle Llc, Chicago | Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen |
| CA2362147A1 (en) * | 1999-02-12 | 2000-08-17 | Steve A. Kolodziej | 1,2-benzothiazepines for the treatment of hyperlipidemic diseases |
| DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
| AU784722B2 (en) | 2000-02-18 | 2006-06-01 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| AU2001247331A1 (en) | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| WO2001068637A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) * | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2002053548A1 (fr) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
-
2002
- 2002-09-05 TW TW091120297A patent/TWI331143B/zh not_active IP Right Cessation
- 2002-09-05 CA CA2459449A patent/CA2459449C/en not_active Expired - Lifetime
- 2002-09-05 DK DK02765013.4T patent/DK1427423T5/da active
- 2002-09-05 WO PCT/GB2002/004033 patent/WO2003022286A1/en not_active Ceased
- 2002-09-05 DE DE60217136T patent/DE60217136T2/de not_active Expired - Lifetime
- 2002-09-05 AT AT02765013T patent/ATE349214T1/de active
- 2002-09-05 HU HU0401196A patent/HU227623B1/hu unknown
- 2002-09-05 IL IL16069102A patent/IL160691A0/xx unknown
- 2002-09-05 NZ NZ531796A patent/NZ531796A/en not_active IP Right Cessation
- 2002-09-05 CN CNA028221133A patent/CN1582151A/zh active Pending
- 2002-09-05 JP JP2003526415A patent/JP3616635B2/ja not_active Expired - Lifetime
- 2002-09-05 MX MXPA04002179A patent/MXPA04002179A/es active IP Right Grant
- 2002-09-05 KR KR1020047003407A patent/KR100935623B1/ko not_active Expired - Lifetime
- 2002-09-05 US US10/488,870 patent/US7132416B2/en not_active Expired - Lifetime
- 2002-09-05 PT PT02765013T patent/PT1427423E/pt unknown
- 2002-09-05 ES ES02765013T patent/ES2278045T3/es not_active Expired - Lifetime
- 2002-09-05 PL PL369078A patent/PL216023B1/pl unknown
- 2002-09-05 EP EP02765013.4A patent/EP1427423B9/en not_active Expired - Lifetime
- 2002-09-05 RU RU2004110716/04A patent/RU2305681C2/ru active
- 2002-09-05 BR BRPI0212346A patent/BRPI0212346B1/pt not_active IP Right Cessation
- 2002-09-05 AU AU2002329387A patent/AU2002329387B2/en not_active Expired
- 2002-09-05 MY MYPI20023317A patent/MY131995A/en unknown
- 2002-09-06 AR ARP020103379A patent/AR037089A1/es active IP Right Grant
- 2002-09-06 UY UY27436A patent/UY27436A1/es not_active IP Right Cessation
-
2004
- 2004-02-16 JP JP2004038919A patent/JP2004210794A/ja active Pending
- 2004-03-02 IL IL160691A patent/IL160691A/en active IP Right Grant
- 2004-03-04 NO NO20040948A patent/NO327041B1/no not_active IP Right Cessation
- 2004-03-04 IS IS7170A patent/IS7170A/is unknown
- 2004-04-06 CO CO04032561A patent/CO5570671A2/es not_active Application Discontinuation
-
2007
- 2007-03-01 CY CY20071100289T patent/CY1106348T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004521961A5 (https=) | ||
| JP2004516285A5 (https=) | ||
| RU2004110716A (ru) | Производные бензотиазепина и бензотиадиазепина, которые ингибируют перенос желчных кислот в подвздошной кишке (ibat), для лечения гиперлипемии | |
| JP4441261B2 (ja) | ベンゾチアゼピン誘導体 | |
| JP4423191B2 (ja) | 高脂血症状態の治療用のチアゼピン基を含むペプチド誘導体 | |
| RU2004134564A (ru) | Химические соединения | |
| AU2002222228B2 (en) | Chemical compounds | |
| RU2333199C2 (ru) | Производные дифенилазетидинона, способы их получения, содержащие их фармацевтические композиции и комбинация и их применение для ингибирования всасывания холестерина | |
| JP2006518728A5 (https=) | ||
| AU691243B2 (en) | Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace | |
| US9585964B2 (en) | Liver targeted conjugates | |
| JP2005536502A (ja) | 下痢の処置用のｉｂａｔ阻害剤および金属塩の組合せ | |
| JP2010533131A5 (https=) | ||
| RU2004116918A (ru) | Производные замещенной фенлпропионовой кислоты в качестве агонистов человеческого пролифератор активированного альфа-рецептора пероксисома | |
| EP1797878A3 (en) | Benzothiazole derivatives | |
| CA2520109A1 (en) | Use of an ibat inhibitor for the treatment or prophylaxis of constipation | |
| CA2429979A1 (en) | Treatment of statin side effects | |
| MXPA04002189A (es) | Derivados de benzotizepina para tratar hiperlipidemia. | |
| RU2006132668A (ru) | Синергетические комбинации, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний | |
| RU2013126119A (ru) | Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты | |
| JP2804177B2 (ja) | 脳内滞留性化合物およびその用途 | |
| JP2008530101A5 (https=) | ||
| MXPA01011302A (es) | Terapias de combinacion para la estimulacion de crecimiento oseo. | |
| JP2004504379A5 (https=) | ||
| CN100482645C (zh) | 逆转和预防心血管疾病的方法 |